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3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA): 
 
 PHARMACOLOGY, TOXICOLOGY, USAGE PATTERNS, AND  
 
NEUROLOGICAL EFFECTS IN HUMANS 
 
ALEXANDER IAN HELFAND 
ABSTRACT 
 3,4-Methylenedioxymethamphetamine (MDMA) is a ring-substituted 
amphetamine with a potential for abuse. Although originally developed by Merck, 
MDMA is an illegal drug that is popular recreationally, and is more recently being touted 
as a therapeutic agent. Unlike some other drugs in the amphetamine class, the 
mechanism(s) by which MDMA produces its subjective effects are not well understood.  
MDMA is a selective serotonin (5-HT) neurotoxin. Exposure to MDMA can lead 
to lasting reductions in brain 5-HT and 5-HT axonal markers. Somewhat paradoxically, 
its acute pharmacological effects involve a dramatic acute increase in serotonin (and 
other monoamine) levels in the brain and the periphery. MDMA is also a direct agonist at 
several different monoaminergic receptors. Although these pharmacological properties of 
MDMA are known, they don’t appear to fully explain the subjective of effects of 
MDMA, which include feelings of well-being and euphoria. One unfortunate notion held 
by many MDMA users is that the drug is safe, or at least safer than many other illegal 
drugs. This is a notion that is strengthened by MDMA’s current and past use as a 
psychotherapeutic agent, although definitive safety/efficacy reports have yet to appear in 
the literature. In recent years, there has been a renewed push to acknowledge the potential 
utility of MDMA in the treatment of conditions such as post-traumatic stress disorder.  
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MDMA has been reported to damage a number of organ systems in addition to its 
properties as a selective 5-HT neurotoxin in the brain. Furthermore, recreational MDMA 
users develop tolerance, which results in a need to increase the dose to achieve the same 
subjective effects, thereby also increasing the risk for dose-related adverse effects. A 
number of research laboratories have demonstrated that abstinent MDMA users develop 
both a loss of brain 5-HT markers, in addition to potential functional consequences of 5-
HT neurotoxicity, including deficits in cognitive function, endocrine modulation, and 
sleep regulation. Although these effects have been well-described, the mechanism by 
which MDMA leads to neurotoxicity remains unclear, and multiple theories have been 
suggested.      
There are many unanswered questions when it comes to MDMA. Without 
knowing more about how MDMA acts in the body and how it produces toxicities, use of 
the drug constitutes a significant risk. Not only are the acute, systemic and potentially 
fatal effects of MDMA problematic, but longer term functional consequences secondary 
to serotonin depletion may pose significant problems for abstinent MDMA users as they 
age. In light of the drug’s popularity, the need for answers and increased public 
awareness has never been more pressing.  
Although MDMA is classified by the Drug Enforcement Agency (DEA) as 
schedule I, popular musicians have begun to positively reference MDMA in their lyrics, 
which has likely contributed to the observed rise in MDMA-related hospital visits and 
fatalities. Communities, parents, and healthcare professionals must make a more 
concerted effort to raise public awareness of the potential dangers of MDMA use.  
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I. Introduction: MDMA Today 
3,4-Methylenedioxymethamphetamine 
 3,4-Methylenedioxymethamphetamine, or MDMA, is a ring-substituted 
amphetamine with a potential for abuse. MDMA has been in existence since at least 
1914.1 MDMA-related hospitalizations have been rising over the past 15 years, as the 
drug increased in popularity2. MDMA has been described as an entactogen3, meaning that 
it heightens feelings of empathy, trust, and belonging. Recreational MDMA users have 
historically been individuals who frequent “raves” and nightclubs.4 This context is 
especially problematic for MDMA use, because the drug produces a rise in body 
temperature, and drug consumption in the warm setting of an active nightclub or similar 
situation may lead to more severe, sometimes life-threatening hyperthermia. Animal 
studies show that the effects of MDMA are compounded by the temperature of the 
ambient environment.5 MDMA is a selective serotonin (5-HT) neurotoxin, while other 
amphetamines may act as a dopamine (DA) neurotoxin or as both a DA and 5-HT 
neurotoxin.6 For reasons that are unclear, MDMA is a selective 5-HT neurotoxin in all 
animal species tested to date (as well as humans) with one exception; in mice, MDMA is 
a selective DA neurotoxin.7 MDMA-mediated 5-HT neurotoxicity is defined by long-
lasting depletion of brain indole markers after the drug has left the body, including 5-HT, 
5-hydroxyindoleacetic acid (5-HIAA), and serotonin reuptake transporters (SERTs). 
MDMA is neurotoxic only to neuron terminals and axons, largely sparing the cell body or 
soma. In addition to its selective 5-HT effects, MDMA exerts acute toxicity on many 
different organ systems and possesses a diverse set of pharmacological properties, 
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although the present focus will be mainly on the neural effects and the mechanisms by 
which MDMA might produce long-lasting neurotoxicity, as well as on relevant 
pharmacology and drug metabolism. Both the long-term and acute effects of MDMA will 
be discussed.   
Why Take MDMA? 
 As one user explains, “All I wanted to do was smile, I was so wide awake, 
and I felt in love for everything and everyone.”8 MDMA has been described as an 
“entactogen”, enhancing feelings of love, trust, and emotional closeness, in addition to 
these “entactogen” properties, MDMA is an amphetamine and, as such, has stimulant 
properties typical of this drug class. Individuals may choose to take a drug for many 
different reasons, but MDMA has historically been classified a “club drug” 9, a drug for 
partying, having a good time, and staying awake. When taking the drug at a concert, the 
purpose may be to change the subjective perception of the sensory experience, as users 
report experiencing altered perception in both light and sound.10 These effects usually 
peak within two hours of administration.11 MDMA is often sold as a tablet12, which 
allows users to take the drug discretely. In the setting of a loud concert or nightclub, 
behavioral effects like euphoria and a heightened energy level do not draw any unwanted 
attention. In recent years, MDMA use has become especially common13 in private homes, 
and a 2009 review of MDMA-related fatalities found that the majority of the MDMA use 
occurred in private homes.14 
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Variations in Drug Composition 
MDMA has many names on the street, including “ecstasy” and, more recently 
“molly”. 15 It is worth noting that not all “ecstasy” tablets contain pure MDMA. In 1997, 
ecstasy tablets from Holland were tested and only 34% were found to contain MDMA. 
However, by 1998, over 75% of Dutch ecstasy contained MDMA. 16 This finding has 
prompted the World Health Organization to treat the term “ecstasy” as an umbrella term 
referring to several different compounds. Ecstasy may contain 3,4-methylenedioxy-N-
ethylamphetamine, also referred to as MDEA or MDE. MDE has been called “Eve”16, 
indicative of the similarities between the effects produced by MDE and those produced 
by MDMA, which has also been called “Adam”.16 Ecstasy may also contain 3,4-
methylenedioxyamphetamine, better known as MDA, or the “love drug”.17 While MDA 
is a drug of abuse in its own right, it is also a metabolic product of MDMA and also a 
serotonin neurotoxin5,18,19. The three compounds mentioned above (MDMA, MDA, and 
MDEA) are chemically related, and produce similar effects pharmacologically.20–22 
Reference will be made to ecstasy with the assumption that the tablets in question contain 
MDMA, but this is not always the case.1 Still, relatively pure MDMA is present and 
available for drug users; anecdotal reports of seizures by police in Liverpool, UK 
describe the MDMA seized as “pure” and “almost crystalline”.4 
History of MDMA 
Merck first applied for a patent on MDMA in 1912, and the patent application 
was granted in 1914.16 The patent was granted in Germany, and suggests that MDMA 
was only to be an intermediate compound used in the production of other therapeutics.16 
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The drug was relatively unknown until 1953, when the U.S. Army conducted a study 
exploring MDMA’s toxic potential. The research was declassified in 1969, and published 
in 1973.16 Several years later, in 1976, Dr. Leo Zeff, Ph.D., began to use the substance as 
a supplement to psychiatric therapy.16 A comprehensive review detailing the use of 
MDMA in psychotherapy was not published until 1983. At that time, the drug’s 
popularity in the psychotherapeutic community was on the rise, although initially, results 
of MDMA-assisted sessions were not made public for fear of attracting the DEA’s and 
public media’s attention to this new drug.16 The drug picked up the name “ecstasy” in 
1981, and recreational use of MDMA expanded thanks to mass production by organized 
groups of chemists and shameless promotion as a “fun dance drug” 16 The rapid 
explosion of MDMA’s recreational use finally alerted law enforcement and the 
therapeutic communities. As a result, in 1984, the DEA recommended that MDMA be 
classified Schedule I, a status shared with drugs such as heroin, which would make the 
drug illegal. Psychotherapists fought back, to the surprise of the DEA, which was 
unaware of the drug’s purported therapeutic value.16 Meanwhile, mass production of the 
drug continued. The DEA responded by scheduling the drug emergently, classifying it 
Schedule I for a period of one year while hearings took place. For a drug to be classified 
Schedule I, there must be a high potential for abuse, no accepted medical use, and an 
inability to make medical use of the drug safe.23 The courts recommended the substance 
be classified Schedule III.16 The DEA rejected this recommendation, and with the 
exception of a brief (three month) removal of Schedule I status due to an appeal made by 
a medical doctor, the drug has remained classified Schedule I.16  
	  5	  
Therapeutic Uses for MDMA 
As mentioned above, some maintain that MDMA has a role in psychotherapy, 
despite the significant body of literature that describes the damage MDMA can 
potentially inflict on the brain and bodily organs. Such arguments often claim that the 
negative outcomes associated with MDMA have been overstated. MDMA’s therapeutic 
potential has been proposed on account of its ability to promote “relaxation”, “facilitate a 
loosening of the ego”, and “encourage an increased thoughtfulness and 
contemplativeness”.24 Together, these qualities are said to promote enhanced insight and 
an increased ability to explore “painful repressed memories”.25,26 Proponents have cited 
the use of MDMA in couples therapy, where it was used in place of LSD.27 Others 
suggest that it might be useful in treating chronic pain, another utility with previously 
documented success.25 In this case, a patient suffering from multiple myeloma received 4 
MDMA treatments over the course of 9 months. The patient reported complete 
alleviation of his pain during the treatments. Although the pain returned during the 
interim between sessions, the patient claimed that he was able to manage the pain by 
recalling his experiences with MDMA. The treatments ceased once MDMA was made 
illegal. The pain eventually returned, and the patient died of his illness. 25 Still others 
have recently demonstrated the success with which MDMA can be used to treat post-
traumatic stress disorder (PTSD).28 Currently, the Multidisciplinary Association for 
Psychedelic Studies (MAPS) is funding clinical trials to investigate the efficacy of 
“MDMA-assisted psychotherapy” in the treatment of PTSD, with the goal of an FDA-
approved form of MDMA on the market by the year 2021.29  
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Many who advocate for the therapeutic effects of MDMA refer to a study by 
Halpern et al. in which the authors were unable to find any lasting residual cognitive 
effects of MDMA use.30 Halpern et al. suggest that MDMA use alone might “not 
generally produce lasting residual neurotoxicity.”30 Halpern et al.’s results and 
conclusion have prompted several responses,31,32,33 including reevaluations of the data. 
Responding to the author’s conclusion that MDMA use might not cause toxicity, A.C. 
Parrott offers “a rather different interpretation of their findings”33, and suggests that 
Halpern et al. have only demonstrated the dramatic variability of the effects produced by 
MDMA. Currently, groups like MAPS are spending large amounts of money on clinical 
trials in order to test the efficacy of MDMA as an adjunct to psychotherapy.29 Such 
reports are likely to contribute to the mistaken notion that MDMA is “safe”.34,5 As 
previously noted, the repeated use of MDMA may be problematic, because tolerance to 
its subjective effects develops quickly, requiring higher dosages to achieve the same 
subjective response. If such tolerance occurred, the potential therapeutic benefit of 
MDMA may become limited. Tolerance to MDMA will be discussed subsequently. In 
addition to the problem of tolerance, 25% of users report the occurrence of at least one 
adverse reaction to the drug.8 In some individuals, especially those with a genetic 
predisposition, MDMA can induce a panic attack, and, in some individuals, such an 
attack can bring about the development of panic disorder. 1,35 When MDMA-induced 
panic attacks do occur, they are generally within the first hour after administration, and 
they occur more frequently in women.1,35 
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Public Health Concerns 
 MDMA is widely used, and population surveys indicate that it is among the most 
widely used illegal substances in the world.4 Popular musicians such as Jay-Z, Madonna, 
and Miley Cyrus, promote “molly”, slang for molecular MDMA, in their lyrics and 
performances15. The inclusion of the drug in popular culture can only add to the drug’s 
appeal, especially to younger audiences, and may contribute to the notion widely held by 
many users of MDMA that the drug is “safe”34,5. Between 1997 and 1999, the prevalence 
of MDMA use among nearly all types of college students rose from 2.8% to 4.7%, an 
increase of 69%36. Recent data shows that MDMA use may be rising. Figures published 
by The Drug Abuse and Warning Network (DAWN) estimated that there were 10,227 
emergency department visits related to MDMA in 2004. In 2008, this number increased 
to 17,888. In 2011, they estimated over 22,498 emergency department visits related to 
MDMA.2 Unfortunately, these figures are likely underestimates of what is actually 
occurring; not every health care provider reports to DAWN, and not every drug-related 
emergency department visit is accurately reported, as drug users may be reluctant to share 
information concerning drug use with health care providers.37 In addition to its popularity 
in the United States, MDMA is also widely abused in Europe.1 As recently as 2013, a 
raid coordinated by European police in three countries seized 60 million ecstasy tablets 
estimated to be worth €1.3 billion.38 The public health problem associated with MDMA 
may be worsened by reports of healthcare professionals who advocate for the use of 
MDMA in the treatment of various psychological disorders.25 One website, 
“theDEA.org”, which the webmaster states is an acronym for “Drug Enjoying 
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Americans”,39 states prominently at the top of its homepage that “MAPS has officially 
gotten approval from the FDA (US government) to begin testing MDMA ('ecstasy') on 
military veterans with post-traumatic stress disorder (PSTD)!”40 Elsewhere, on the same 
website’s page covering neurotoxicity, the webmaster states that “science has proven (at 
least in my opinion) that moderate MDMA use does not cause any lasting harm...”41 
 Addiction and Behaviors Associated with MDMA 
The National Institute on Drug Abuse (NIDA) classifies MDMA as a “club drug”, 
commonly used by individuals who frequent nightclubs and raves.9 Within that group, 
ecstasy use can be commonplace. A study in 2001 suggested that as many as 96% of 
club-goers have used the drug4,42, indicating that the present increase in MDMA use may 
be part of a long lasting pattern.  MDMA users now include a wide range of groups and 
ethnicities.9  
While the drug has an addictive potential, physical dependence is unlike that 
observed with other types of drugs, such as opioids.43 Bruno et al. suggest that the 
“underlying structure of dependence symptoms differs for ecstasy compared to other drug 
classes”44. MDMA is not a drug that engenders a state of physical dependence such that 
regular administration of the drug is required in order for the user to feel “normal”, as 
may be observed in chronic heroin users.45 However, MDMA users have self-reported 
withdrawal symptoms and tolerance, both of which are hallmarks of physical 
dependence.43 Degenhardt suggests “the biological basis for a dependence syndrome 
similar to other drugs is present, but that other issues, for example, behavioral 
reinforcement or learning, may additionally play a role for some.”43 In humans, one 
	  9	  
pattern of MDMA usage is similar to that observed with hallucinogens such as LSD; drug 
users commonly undergo a “two-factor structure” consisting of compulsive use followed 
by escalating use.43 Frequent users experience profound tolerance4,8, and self-administer 
increasingly large quantities of MDMA as the subjectively experienced “positive” effects 
begin to decline. Although uncommon, there are accounts43,46,47 of intravenous MDMA 
use; one study by Topp et al. found that 16% of a large sample of Australian recreational 
MDMA users had injected the drug.48 Additionally, some individuals may consume the 
drug by insufflation.8 Users now report taking the drug in a diverse array of 
environments13: MDMA use is no longer restricted to nightclubs, and its classification as 
a “club drug” has become misleading, especially in light of reports of individuals dying 
after taking MDMA in private homes13. Regardless of the expansion of the drug into 
wider audiences, club-goers were fourteen times more likely to have used the drug, and 
about 90% of club-going individuals in the UK have reported use.1  
	  10	  
II. Chemical Properties 
Chemical Structure and Properties 
Figure 1: Chemical Structure of MDMA  
 As shown in Figure 1, MDMA is a ring-substituted amphetamine, and a chiral 
compound. Its enantiomers may exhibit slight differences in their properties. Current 
research indicates differences in the metabolism and activities of the enantiomers49, 
although the functional effect of this finding is not clear. MDMA is highly lipophilic, and 
fairly small in size (193.24 amu49) which allows the drug to readily cross the blood-brain 
barrier. It is these same properties that may allow MDMA to diffuse across a cell 
membrane. Although usually administered as a racemic mixture50, both enantiomers are 
potent in generating the desired subjective effects. The S(+) enantiomer is more potent, 51 
and more easily induces “euphoria, energy and a desire to socialize.”50 The S(+) 
configuration is also eliminated more rapidly.51   
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Similarities to Other Compounds 
Figure 2: Chemical Structures of MDMA, Mescaline, and Related Compounds.  
MDMA is structurally related to amphetamines and the hallucinogen                            
mescaline. 52 In fact, the only chemical difference between MDMA and 
methamphetamine is the addition of a substituted ring on the other side of the molecule. 
In addition to its effects on the brain, MDMA affects several other organ systems, and 
those effects may be similar to those produced by related compounds. For example, in 
rats, MDMA produces cardiovascular effects similar to those elicited by d-
amphetamine.53  
 
III. Pharmacodynamics 
Neurochemistry Overview 
MDMA, like many amphetamines, is a strong central nervous system (CNS) 
stimulant. MDMA is a so-called indirect agent because it exerts its effects primarily 
through release of 5-HT and other monoamines rather than by direct actions on 
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monoaminergic receptors.  MDMA exhibits a high affinity on presynaptic serotonin 
transporters (SERTs) located in the nerve terminals. One hypothesis posits that once 
MDMA reaches the brain, it is co-transported with Na+ into the terminal via SERT, 
competitively inhibiting 5-HT uptake.54 Once inside the cell, MDMA is carried into the 
storage vesicles by the vesicular monoamine transporter (VMAT). Concentrations of 5-
HT may increase in the vesicle, and 5-HT will be pumped out into the cytosol by the 
VMAT.  As a result, cytosolic 5-HT and Na+ levels rise.  Cellular 5-HT is further 
increased by MDMA-mediated inhibition of the monoamine oxidase (MAO), which 
normally metabolizes 5-HT.  5-HT binds to the now inward facing SERT and, together 
with Na+, is transported out of the terminal into the synaptic cleft where it activates 
postsynaptic receptors.54 Transporting MDMA has effectively ‘reversed’ the flow of 
SERT. 
Normal 5-HT Activity 
A brief overview of normal serotonergic transmission is necessary to better 
understand why the effects of MDMA on the 5-HT systems are so damaging. Ordinarily, 
5-HT is stored within the neuron in vesicles, having been packaged by the vesicular 
monoamine transporter (VMAT)55(p141). This keeps concentrations of free 5-HT within 
the neuron at acceptably low levels. In a serotonergic neuron, many different signals can 
cause a 5-HT containing vesicle to merge with the cellular membrane, allowing vesicular 
release of the 5-HT into the synaptic cleft, where an effect is produced due to the binding 
of 5-HT on the post-synaptic (and pre-synaptic) receptors. There are many different types 
of 5-HT receptors, and at least three different types of 5-HT2 receptors56(chap13), but all 
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researched 5-HT2 receptors are classified as G protein coupled receptors (GPCRs) 
56(chap13). This means that after 5-HT (or a 5-HT agonist) binds to the receptor, 
pharmacologic effects are produced by way of second messengers; a cascade of such 
second messengers amplifies the signal produced. When 5-HT interacts with a receptor, a 
variety of effects may be produced, depending on the type of receptor and its location and 
function. Activation of many types of 5-HT receptors may lead to neuronal activation or 
“depolarization”, but 5-HT1 receptors do not perform this function. 5-HT1 receptors may 
be called “autoreceptors” because they are located on the presynaptic neuron, the neuron 
which is releasing the 5-HT. 5-HT1 receptors are also GPCRs. In general, the function of 
an autoreceptor is to modulate the amount of neurotransmitter released by the neuron. 
The family of 5-HT1 receptors is the only known 5-HT receptor family which modulates 
the release of 5-HT. From the synaptic cleft, 5-HT can be taken back up into the axon 
where it is metabolized by monoamine oxidase (MAO)55(p141).  
Cellular Consequents of MDMA Activity 
MDMA binds to all three monoaminergic transporters (i.e., serotonergic, 
dopaminergic and noradrenergic) and is an indirect monoamine agonist.57 Although 
MDMA binds to all three monoaminergic transporter, it largely targets the 5-HT system, 
and up to 80% of presynaptic 5-HT may be dumped into the synaptic cleft upon 
administration.58 In addition to the previously described effect on the SERT, elevated 
synaptic levels of 5-HT are caused by increased vesicular release, reduced pre-synaptic 
reuptake, and reduced MAO activity.10 In addition, MDMA exhibits comparably high 
affinities for several receptors including the 5-HT2 receptor, as well as the α2 adrenergic, 
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H1 histamine, and M1 muscarinic receptors.10 MDMA exhibits somewhat lower affinity 
binding at the 5-HT1, α1 adrenergic, M2 muscarinic, and β adrenergic receptor.10 MDMA 
additionally exhibits similarly low binding affinities for the D1 and D2 DA receptors.52 
Although early experimentation initially suggested that MDMA exhibited little selectivity 
for the 5-HT1 receptor compared to the 5-HT2 receptor, subsequent research has 
demonstrated otherwise.59 Additionally, MDMA has been demonstrated to act on 
VMAT.60,61 VMAT is a key player in the storage of neurotransmitter within discrete 
vesicles, and MDMA’s previously described activity at VMAT may lead to elevated 
cytosolic levels of 5-HT.55(p141),60 Free cytosolic 5-HT may increase the oxidative burden 
on the neuron, and would also contribute to elevated extracellular 5-HT due to MDMA’s 
activity on SERT.60 In addition, MDMA has also been shown to cause release of NE due 
to inhibition and/or reversal of the NE transporter (NET).52,60,62 MDMA has also been 
demonstrated to inhibit and reverse the direction of the DA transporter (DAT), increasing 
extracellular DA levels. 52,60,62 The affinity of MDMA for DAT is lower than the affinity 
MDMA possesses for SERT, such that “MDMA releases 5-HT from striatal slices at 
concentrations that are ~10-fold lower than concentrations required for stimulating DA 
release.”52 
With an understanding of where MDMA is active, it is possible to conceptualize 
what MDMA is doing to 5-HT and other neurotransmitter systems. Once in the brain, 
MDMA may enter a serotoninergic neuron in at least two different ways. It can either 
diffuse across the cell membrane, or it can bind to an outward facing SERT. Once inside 
the neuron, MDMA can cause release of 5-HT as described previously. Binding of 
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synaptic 5-HT to post-synaptic 5-HT2 receptors causes the post-synaptic neurons to 
depolarize, pushing them closer to activation.  The net effect of MDMA is to increase 5-
HT neurotransmission, with huge amounts of 5-HT free in the synapse available to 
depolarize post-synaptic neurons. Neurons may become depleted of 5-HT, and this 
problem is compounded by an inability to make more; MDMA inhibits the rate-limiting 
enzyme in the biosynthesis of 5-HT, tryptophan-5-hydroxylase. This effect occurs very 
quickly, and such inhibition can last for days.10,55(p141) 
Acute and Subacute Pharmacodynamic Effects of MDMA Administration 
As reviewed in the previous section, the acute pharmacological effects of MDMA 
include increases in 5-HT, DA, and norepinephrine (NE) neurotransmission in the brain 
and the periphery, in addition to direct actions at a variety of 5-HT and non-5-HT 
receptor types. Its effects at 5-HT neurons are the most prominent,52,63,64 but 5-HT release 
may not alone produce the subjective effects of the drug, as other drugs causing 5-HT 
release, such as the diet drug fenfluramine65, do not produce this subjective response. In 
addition to actions at neuronal targets, MDMA leads to the release of the hormones 
oxytocin and vasopressin, which have also been hypothesized to contribute to MDMA’s 
subjective effects of love, trust, arousal, and belonging.9,66,67 Elevated heart rate, blood 
pressure, and energy level occur following acute administration, and these effects are 
likely due to the action MDMA-induced increases in NE.11 While MDMA can produce a 
wide array of symptoms, one particularly dangerous feature is the tremendous variability 
found in different individuals’ reactions to the drug. Importantly, the effects produced as 
well as an individual’s ability to tolerate them are extremely variable; a dose of the same 
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size can do very different things to different people.68 Not every MDMA experience is 
positive; in addition to adverse reactions, recent studies have shown that MDMA may 
amplify negative emotions as well.4,69,70 Considering undesired effects, the surge of 5-HT 
can cause adverse physical effects if the increase in 5-HT reaches especially high levels, 
a state known as “serotonin syndrome”.8 In more mild states of serotonin syndrome, 
hyperthermia, hyperkinesia, and confusion are observed in the user. In more serious 
cases, seizures, and loss of consciousness may occur.8 In the most severe cases, 
rhabdomyolysis, disseminated intravascular coagulation, multi-organ failure, and death 
may occur. High temperature environments exacerbate the situation and increase the 
likelihood of unfavorable outcomes.71 Serotonin syndrome will be further discussed 
subsequently. While MDMA often causes hyperthermia, experimentation with rats has 
demonstrated that administration in a cool environment can lead to large drops in body 
temperature; indeed, the homeostatic control of body temperature is lost as a result of 
MDMA administration.8 In humans, a similar effect has also been observed. In 2009, 
Greene et al. described 332 cases of patients receiving treatment at a London hospital for 
reactions to MDMA. While hyperthermia was common, other individuals presented with 
low body temperatures or even hypothermia.72. 
In addition to its acute and subacute subjective and physiological effects, MDMA 
may weaken the immune system. MDMA has been shown to suppress the innate and 
adaptive branches of the immune system.73 MDMA may impair a neutrophil’s ability to 
phagocytose, and also interferes with the production of a number of macrophage-derived 
pro-inflammatory cytokines. These cytokines include Tumor Necrosis Factor α, 
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Interleukin (IL) 1-β, IL-15, and IL-1273, to name a few. Subacutely, in the 24 hours 
following administration of neurotoxic dosages of MDMA, the brain is depleted of 5-HT, 
and there is also a marked depletion of 5-hydroxyindoleacetic acid (5-HIAA)74, which is 
the major metabolite of 5-HT. Cerebrospinal fluid (CSF) levels of 5-HIAA can be used to 
indirectly assess serotoninergic injury (including that caused by MDMA) in both humans 
and non-human primates.75,76 With respect to rats, about 24 hours following this period of 
depletion, 5-HIAA levels return to “normal”.1 This return is short-lived; within 3 days, 
levels of 5-HT and 5-HIAA drop once more; CSF levels of 5-HT and 5-HIAA remain 
depressed for at least 12 months.1 The subacute depletion of 5-HT and 5-HIAA may 
cause the user to feel fatigued, depressed, or anxious.9 These feelings are especially 
pronounced in the days that immediately follow drug administration, a phenomenon 
which has been nicknamed the ‘Tuesday blues’ or the ‘midweek blues’.10 Some research 
has suggested an increase in irritability and anger which is worst about four days after 
taking a neurotoxic dose of MDMA.10 In addition to the effects described, MDMA also 
increases levels of the hormone cortisol; some studies have found reported increases in 
cortisol levels during and immediately after MDMA use. Elevated cortisol levels and 
associated dysregulation of the hypothalamic-pituitary-adrenal axis (HPA axis) have been 
conclusively linked to major depression,77 but it is unclear what role cortisol plays with 
respect to the ‘midweek blues’. Long-term alterations in cortisol or HPA axis functioning 
may result in cognitive deficits. 77 
In a review of 12 studies describing human reactions to MDMA administration, 
Dumont and Verkes note that 11 of the studies found a significant increase in cortisol 
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levels following MDMA administration.78 In another separate report, Harris et al. found a 
100% increase in cortisol levels following a dose of 1.0 mg/kg, and a 150% increase 
following a dose of 1.5 mg/kg.79 One study found that cortisol levels may be elevated by 
as much as 800% while under the effects of MDMA.4,80 This finding has been contested, 
as the reported 800% increase is somewhat incredible. In rebuttal, Wolff and Aitchison 
have pointed out the conclusion is somewhat misleading, as the cortisol levels were 
measured differently (total cortisol quantity as compared to salivary cortisol 
concentration). Furthermore, Wolff and Aitchison measured cortisol levels immediately 
after having taken MDMA, while the 800% increase was observed in a dance club. 81–83 
The authors do not dispute the finding that cortisol levels are elevated, but instead clear 
up the apparent incongruency.81 In another study using healthy MDMA-naïve volunteers, 
a 125mg dose of MDMA was found to significantly increase plasma prolactin levels.84 
The acute effects of MDMA include a complex pattern of endocrine changes. 
The Serotonin Syndrome 
Symptoms of serotonin syndrome include “restlessness, confusion, shivering, 
tachycardia, diarrhea, muscle twitches/rigidity, fever, seizures, loss of consciousness, and 
death.”56(chap13) Serotonin syndrome is caused by elevated 5-HT levels, and produces 
symptoms according to the extent of 5-HT toxicity. Mild instances of serotonin syndrome 
generally do not require treatment.8 One especially dangerous component is the 
potentially rapid progression of serotonin syndrome, such that a mild case can become 
quite serious in less than one hour.8 While a mild case can be treated with rest and a cool 
environment, a more serious case may require active cooling of the body, physical 
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restraint, and administration of drugs with 5-HT antagonistic effects in order to prevent 
death.8 Occasionally, the symptoms (but not the cause) of serotonin syndrome may be 
treated with a benzodiazepine.60,85 The cause of serotonin syndrome is not just limited to 
MDMA, but may also occur as a reaction to a combination of drugs administered with 
therapeutic intent, such as drugs of the MAOI and SSRI class.56(chap13) Most MDMA users 
exhibit some degree of serotonin syndrome, and individuals may actually use the 
presentation of serotonin syndrome as a benchmark for establishing the quality and 
MDMA content of the drug which has been taken.8   
Fatal Cases  
Despite the potential confound created by polysubstance use in MDMA users, 
there should be no doubt about the role MDMA plays in the development of potentially 
lethal scenarios. Considering data from UK coroners between 1997 and 2007, Schifano et 
al. found that fatalities subsequent to MDMA use were significantly more frequent than 
fatalities subsequent to methamphetamine use.86 That being said, MDMA, while clearly 
dangerous and potentially lethal, may be less dangerous than other drugs of abuse. 
Emergency department and mortality data suggests that the occurrence of life-threatening 
complications resulting from MDMA ingestion may be less common than those 
associated with other drugs of abuse, such as methamphetamine or opioids.14,87,88 As 
previously discussed, the incidence of complications and fatalities related to MDMA use 
is rising; while MDMA-related complications are currently uncommon, they are 
increasing in frequency. This trend demands future research leading to a better 
understanding of MDMA and how it causes damage. MDMA-induced fatalities vary in 
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their proximate cause of death. Though MDMA causes hyperthermia, Smith et al. 
describe MDMA-induced fatalities resulting from acute liver failure89; MDMA is known 
to cause cultured rat liver cells to undergo apoptosis.90 In other fatal cases involving 
MDMA usage, the causes of death have included seizures, rhabdomyolysis, cardiac 
arrest, multiple types of organ failure (including renal failure and liver failure), and even 
disseminated intravascular coagulopathy.4 Many of these pathologies can be caused by 
hyperthermia itself.14 Due to the many different organ systems affected by MDMA, 
MDMA-related fatalities are not a homogenous group of cases, and many involve 
preexisting conditions or other illegal substances. Kaye et al. considered 82 MDMA 
related fatalities in Australia which spanned 5 years. They observed that 59% of the 
fatalities were attributed to a mixture of other drugs in addition to MDMA.14 We have 
primarily focused on the pharmacology and neurological activities of MDMA, but 
cerebrovascular pathologies were found in only 12% of cases considered by Kaye et al. 
Instead, cardiovascular pathologies were found in 58% of the fatalities examined. 5-HT 
performs a wide variety of functions both within the brain and the periphery, and perhaps 
the most salient of these functions relate to blood pressure. In the brain, 5-HT1D 
activation causes constriction of cranial blood vessels. In smooth muscle, such as is found 
surrounding most blood vessels, 5-HT2A activation causes vasoconstriction, raising blood 
pressure.56(chap13) Vasoconstriction of capillaries prevents the efficient loss of heat through 
radiation, potentially exacerbating a state of hyperthermia. When vasoconstriction is 
coupled with tachycardia, resulting from MDMA or anything else, the result is typically 
an acute increase in blood pressure. When the individual finds himself dancing in a hot 
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and crowded environment, the effect can only be to further increase blood pressure, and 
so increase the risk for life-threatening complications. Indeed, hypertension is just one of 
the acute effects of MDMA ingestion. It is therefore not surprising that cardiovascular 
pathologies were found by Kaye et al. in the majority of the cases they considered. 
Although uncommon, there are cases of MDMA-induced aortic dissection91 as well as 
MDMA-induced myocardial infarction.92,93 The role of unknown pre-existing conditions 
cannot be understated: aneurisms and arteriovenous malformations significantly increase 
the likelihood for vascular complications of MDMA use. While we have discussed 
several ways that MDMA seems to be more dangerous in women, Kaye et al. found that 
83% of the deceased were male.14 Whether this is due to behavioral differences (e.g., 
males may take higher dosages or behave differently when under the influence of 
MDMA) or to biological differences between males and females remains unclear. The 
incidence of various pathologies and causes of death bears further consideration. Of the 
82 cases considered, MDMA was the proximate or antecedent cause of death in 67 cases. 
Of these 67, drug-induced toxicity was observed in 91% of cases.  
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Table 1a: Incidence of Various Findings in 67 MDMA-Related Deaths14  
Cause of Death Incidence 
Cardiovascular 10% 
Cerebrovascular 7% 
Aspiration 4% 
Pulmonary 3% 
Hyperthermia 1% 
Of the cardiovascular complications, atherosclerosis was the most common 
pathology observed, having been identified in 6 cases.14 Atherosclerosis reduces the 
diameter of affected vasculature, contributing to the previously described hypertension. 
Kaye et al. reviewed other cases from a variety of sources, including autopsy findings. 
The authors found atherosclerosis to be a common pathology in many of the fatalities 
reviewed. Of the cases previously described in Table 1, it is interesting that hyperthermia 
was the proximate cause of death in only 1% of the 67 cases, although it is possible that 
hyperthermia acted as an antecedent cause, initiating or worsening other life-threatening 
conditions. In two cases considered by De Letter et al., the proximate cause of death was 
found to be hyperthermia68 wherein the body loses the ability to regulate temperature due 
to “altered hypothalamic control”8. Many MDMA users are aware of the potential for 
MDMA to produce hyperthermia and dehydration, and attempt to compensate by 
drinking large amounts of water, and perhaps by taking breaks from physical exertion. 
However, drinking large amounts of water poses a new risk; some MDMA users actually 
consume too much water, which can lead to hyponatraemia, another potentially fatal 
condition.8 Hyponatraemia, like 5-HT syndrome can induce an altered mental state and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a Adapted from Kaye et al., 2009. Used with permission. 
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confusion, and may also cause cerebral edema.14,87,94,95 The study by Kaye et al. reported 
an unexpected finding related to fatalities following MDMA use; their data demonstrated 
that the majority of the fatalities considered did not occur in nightclubs, but instead 
occurred in private homes14. This finding demonstrates the danger that MDMA poses 
even outside of a hot and crowded environment, and demands a reevaluation of the 
contexts in which MDMA is being used. Furthermore, the large proportionb of deaths 
directly caused by combined drug toxicity reflects the fact that polydrug use is the norm 
among MDMA users”.14 
SERT-Blocking Compounds  
Fluoxetine, better known to consumers as Prozac, is a selective serotonin reuptake 
inhibitor (SSRI), which interacts with MDMA in interesting ways. In animal models, the 
co-administration of fluoxetine (or any other SSRI) in conjunction with MDMA has been 
shown to prevent MDMA-induced neurotoxicity.96 That being said, fluoxetine is not a 
universally effective way to prevent the effects of MDMA; hyperthermia still occurs.96   
The ability of SSRIs to provide neuroprotection can be measured in a variety of ways, 
including a method called autoradiography.  In particular, by radioactively labeling a 
drug or marker that is known to bind to the serotonin terminal (e.g., 3H-paroxetine, which 
binds to the SERT), it is possible to measure the density of 5-HT terminals in animals 
previously treated with MDMA. 4,97,98 For example, in rats, after giving a single dose of 
MDMA (15 mg/kg), there was a marked reduction of 5-HT and 5-HIAA in the striatum, 
cortex, and HPC. Seven days later, the rats demonstrated significantly reduced 3H-	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
b 44 of the 67 deaths described in Table 1 were due to polydrug toxicity. 
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paroxetine density in the cortex.96 In a different paradigm, 10 mg/kg of fluoxetine was 
given 5 minutes before and 55 minutes after the 15 mg/kg MDMA dose. Consequently, 
indole content was not lost, and the reduction in SERTs was attenuated.96 In still another 
paradigm, fluoxetine (2x 10 mg/kg doses, separated by one hour) was given either 2 or 4 
days before administration of MDMA. In these cases, the result was complete 
neuroprotection.96 Fluoxetine had no effect on the amount and concentration of MDMA 
in the brain,96 but other studies suggest that fluoxetine may increase the concentrations of 
MDMA in the blood.60 Fluoxetine may inhibit CYP2D6c, and MDMA CMAX was found 
to increase by 30% in rats pre-treated with fluoxetine.60 In humans, pretreatment with 
fluoxetine was found to cause an attenuation of the physiological and subjective effects 
of MDMA administration in some studies,99 but not in others.100 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
c CYP is a prefix used for naming cytochromes of the P450 family of cytrochomes, enzymes 
usually found in the liver. 
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IV. Pharmacokinetics 
MDMA Metabolism in Humans 
Figure 3: MDMA Metabolic Pathways19,51,57,d 
 
MDMA is metabolized through two different phase I pathways which operate in 
unison but at different rates in different species; O-demethylenation predominates in 
humans and in nonhuman primates. The goal of the metabolic process is the conjugation 
of the substrate with a sulfate or glucuronic acid moiety in order to render the product 
more prone to renal clearance. Hartman et al. note that N-demethylation is mediated by 
CYP1A2 and by CYP2B6, while O-demethylenation is mediated by CYP2D6.11 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
d Adapted from Mueller et al., 2013. Used with permission.  
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Considering the stereoselectivity of the cytochrome P450s, Meyer et al. found CYP2B6 
to be a very large contributor to N-demethylation activity.51 It should be noted that 
multiple P450 cytochromes are capable of performing demethylation and 
demethylenation reactions, but with varying efficiency. In addition to the reactions shown 
above, HHMA and HMMA are susceptible to N-demethylation, generating HHA and 4-
hydroxy-3-methoxyamphetamine. It is important to note that the O-demethylenation 
reaction, which is mainly catalyzed by CYP2D6 in humans, is subject to inhibition by 
MDMA. Consequently, the progression of MDMA metabolism in humans is not linear, 
because plasma concentrations of MDMA as low as 125-200 ng/ml can inhibit CYP2D6, 
such that a single dose is sufficient to block one of the metabolic pathways for MDMA 
breakdown.19 In human liver microsomes, such inhibition was found to decrease the 
production of the metabolite HHMA by as much as 75%.60 A single recreational dose of 
MDMA may be enough to inactivate most hepatic CYP2D6; a dose of 1.5 mg/kg is 
capable of causing rapid inhibition of CYP2D660. Although recovery of CYP2D6 activity 
is slow, possibly taking 10 days for complete recovery,60 the recovery half-life for 
CYP2D6 is about 2 days. As a result, a second dose of MDMA taken within a few days 
of the first is much more likely to produce toxicity due to elevated concentrations of 
MDMA in the blood exacerbated by diminished metabolic capabilities60 Rietjens et al. 
have suggested that frequent MDMA users may have permanently reduced CYP2D6 
activity.60 Another result of CYP2D6 inhibition is an increased amount of MDMA 
available for N-demethylation, which results in increased amounts of the metabolite 3,4-
Methylenedioxyamphetamine (MDA). MDA’s metabolism is slowed dramatically, as O-
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demethylenation is now inhibited, causing an even larger build up of MDA. MDA is 
biologically active, and acts on many of the same substrates as MDMA, and is also a 
serotonin neurotoxin.1 The inhibition of CYP2D6 has consequences for further 
downstream metabolic products as well; plasma concentrations of HHMA and HMMA 
remain the same despite larger doses of MDMA.57 Furthermore, this inhibition causes 
disproportionately large increases in plasma and brain MDMA concentrations following 
small increases in dose, an example of the non-linear nature of MDMA metabolism.  
Most if not all of the metabolic products of MDMA, as well as the parent drug 
itself, are eliminated in the urine. A full urinalysis was performed on ten individuals to 
further elucidate the major methods of MDMA elimination. In this study, subjects 
received either 1.0 mg/kg or 1.6 mg/kg of oral MDMA. The major metabolite was 
conjugated HMMA-sulfate, which was present in 98% of the urine analyzed.101  
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Table 2: Proportions of MDMA Metabolites in Human Urine101 
Compound Proportion of positive 
urine samples 
MDMA .63 
HHMA .32 
HHMA 3-glucuronide .51 
HHMA 4-glucuronide  .40 
HHMA 3-sulfate .69 
HHMA 4-sulfate .59 
HMMA .38 
HMMA glucuronide .84 
HMMA sulfate .98 
MDA .42 
HHA .03 
HHA glucuronides .13 
HHA sulfates .32 
HMA .23 
HMA glucuronide .51 
HMA sulfate .50 
Urine was collected for 7 days following MDMA administration, although a negligible 
amount of the original dose was excreted in the urine after day 5. Overall, the amount of 
the original MDMA dose recovered in urine ranged from 24% to 52%.101  
Kinetic Profile: CMAX, TMAX, T1/2, and AUC∞ 
T1/2 , also called the half-life, is the time required for the body to remove one half 
of the administered compound from the body, either by excretion or metabolism. The 
following half-lives were determined by Kolbrich et al. for MDMA and its metabolites in 
humans after controlled MDMA administration. 
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Table 3: MDMA Metabolite T1/257 
Compound T1/2 
MDMA 7-8 hrs 
MDA 10.5-12.5 hrs 
HMMA 11.5-13.5 hrs 
HMA Highly variable 
It may take as many as five to six half-lives for 95% of administered MDMA to be 
cleared from the body.102 The time required to reach maximum plasma concentration, or 
TMAX, is dependent upon a number of circumstances, including the chemical structure and 
molecular weight of the drug, its pH, the pH of the environment, the lipophilicity of the 
drug, and other factors. In the case of MDMA, TMAX was about 2.4 hours, regardless of 
the dose administered.57 The numerical value of CMAX varies depending on the size of the 
dose and the size of the subject, but those who receive a “high dose” achieve a larger 
CMAX than those receiving a “low dose”.57 The AUC∞,or area under the plasma 
concentration-over-time curve, is related to the bioavailability of the drug. AUC is an 
especially important variable, because it measures how much of the administered drug is 
actually available and absorbed by the body, a necessary step for the action of most 
drugs. In the case of the study performed by Kolbrich et al., the “high dose” was 1.6 
times larger than the low dose, however the MDMA AUC∞ for the “high dose” was 1.9 
times larger than that found with the “low dose”. This finding indicates a non-linear 
relationship between dose and plasma concentration.57 Such a non-linear relationship is 
most likely caused by the inhibition or saturation of the metabolism of MDMA. 
Interestingly, such a non-linear relationship was not found by Hartman et al., although 
this may be because AUC0-3h was considered, rather than AUC∞.11  
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MDMA and Metabolite Detection Windows 
One parameter of interest was the amount of time until MDMA taken orally 
appeared in the plasma.  
Figure 4: Time Until Metabolite Appearance in Blood57 
 
Following administration, it is apparent that MDMA is quickly being broken down by O-
demethylenation prior to O-methylation, resulting in the formation of HMMA. 
Inhibition/saturation of CYP2D6 by MDMA may cause a relative increase in the amount 
of N-demethylation occurring due to a greater availability of substrate. This results in 
increased MDA formation. Also of interest, Kolbrich et al. report that the detection 
windows for MDMA, HMMA, and MDA are much larger than have been previously 
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documented.57 HMMA had the largest detection window, and was found in the plasma of 
all but one research subject 47 hours after MDMA administration. Depending on whether 
the subjects received the high dose (1.6 mg/kg) or low dose (1.0 mg/kg) group, HMMA 
was still present in the plasma 71 hours after administration in 67% and 14% of subjects, 
respectively.57 Concerning MDMA, the drug was found in every subject’s plasma for at 
least 23 hours after administration.  After 47 hours, 82% of subjects in the “high dose” 
group were found to have MDMA in their plasma, while 23.5% of subjects in the “low 
dose” group were still found to have MDMA in their plasma. MDA plasma 
concentrations resemble MDMA concentrations, and at 47 hours, 24% of those receiving 
the “low dose” of MDMA still had MDA in their plasma, while 82% of those receiving 
the “high dose” had MDA in their plasma. While metabolite concentrations vary from 
subject to subject, HHMA concentrations were found to be especially variable.57 In sum, 
it is apparent that MDMA remains in the body for several days after administration, and 
its metabolites may take even longer to be cleared. Due to the ways in which MDMA is 
metabolized, it is likely that MDMA elimination is also biphasic.103 It is worth noting that 
the inhibition of CYP2D6 affects the metabolism of a single dose of MDMA, but also has 
longer lasting effects which become apparent on repeat administration. In a study by 
Farré et al., two doses of MDMA were given to human subjects, with 24 hours in 
between doses.104 Compared to the first dose, MDMA CMAX increased by 30%, and AUC 
increased by 75%.60,104 These increases were larger than can be explained by a buildup of 
MDMA from the first and second doses, which suggests that autoinhibition of CYP2D6 
is to blame for the increase.60  
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Pharmacokinetic Parameters of MDMA Metabolites 
Concerning the metabolite HMMA, CMAX was nearly identical in both the “high 
dose” and “low dose” conditions.57 HMMA is a product of O-demethylenation followed 
by O-methylation. Saturation/inhibition of the O-demethylenation reaction is likely to 
explain the similar CMAX found for HMMA observed in both administered dosing 
conditions.53 Furthermore, HMMA TMAX was reached significantly more quickly than 
MDMA TMAX,57 indicating saturation/inhibition of the O-demethylenation reaction 
(which creates HMMA) even before complete absorption of MDMA from the alimentary 
canal took place. Due to inhibited formation of HHMA, the ratio of HMMA:MDMA was 
higher in the “low dose” condition than in the “high dose” condition.57 Concerning the 
metabolite MDA, it then follows that the MDA:MDMA ratio would increase over time in 
both dosing conditions as MDMA is broken down by N-demethylation. Kolbrich et al. 
found that “MDA/MDMA ratios increased linearly and similarly from 0.75 to 
approximately 23 hours…”57 MDA CMAX  was attained approximately 7.5 hours after 
MDMA administration, and TMAX was not found to significantly vary depending on the 
size of the dose.57 Such a finding is demonstrative of zero order kinetics.  Conversely, 
both MDA CMAX and AUC were significantly different between the “high dose” 
condition and the “low dose” condition, with larger CMAX  and AUC occurring in the 
“high dose” condition.57 This finding is likely due to inhibition of the O-demethylenation 
reaction leading to increased MDA generation by N-demethylation. As HMA is a 
downstream product of MDMA metabolism, (MDMA à MDA à HHA à HMA), the 
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dose dependent differences in MDA CMAX are reflected in HMA CMAX, such that the 
“high dose” condition had a larger HMA CMAX.57  
Stereoselective Metabolism 
The stereochemistry of MDMA influences the stereochemistry of its resulting 
metabolic products. Enzymes involved with MDMA metabolism, notably the cytochrome 
P450 family, are stereoselective51. Consequently, the R and S configurations are 
eliminated from the body at different rates, and may possess different activities. Because 
of these differences, plasma concentrations ratios of MDMA and its metabolites (such as 
HHMA, HMMA, and MDA) differ over time. The proximal cause of MDMA-induced 
toxicity remains a topic of debate, and one idea suggests that the metabolic products of 
MDMA breakdown may be more damaging than MDMA itself, a hypothesis which will 
be revisited subsequently. A better understanding of MDMA stereochemistry and of the 
properties of its metabolites may prove relevant. Meyer et al. believe that many 
pharmacokinetic parameters differ between racemates in part because of the 
stereoselective nature of CYP2C19 and CYP2D651, among others. Pharmacokinetic 
parameters such as CMAX differed between racemates, such that the R configurations of 
MDMA and HHMA achieved a significantly higher CMAX.50 Conversely, the S 
configuration of HMMA and MDA achieved significantly higher CMAX.50 The two 
MDMA racemates do not show the same dose-concentration curves.50 Five days after 
administering 1.6 mg/kg of racemic MDMA to ten healthy volunteers, Schwaninger et al. 
found significant differences in the quantities and proportions of relevant chiral 
compounds which were excreted in urine. Of the compounds considered (including the 
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administered drug as well as metabolic products), a median of 21% of all excreted 
products were in the R configuration, while a median of 17% were in the S 
configuration.50 In the 2 days following administration of racemic MDMA, the S 
configuration was cleared from body plasma more rapidly, a result of the stereoselectivity 
of metabolic processes.50 The R configurations of MDMA and HHMA were excreted in 
significantly higher quantities, while the S configuration of HMMA was excreted in 
significantly higher quantities.50 No significant difference was found in the R/S 
proportion of excreted MDA.50 Interestingly, the R/S proportion of excreted compounds 
changed over time. Several compounds, including MDA and HMMA, were largely 
eliminated in S configuration in the first 24 hours following drug administration, but 
increasing amounts of R enantiomers appeared over time.50 The authors note significant 
variability in the proportions and stereochemistry of excreted metabolites over time 
between subjects, but the final R/S ratios for excreted metabolites between subjects was 
somewhat more consistent50, suggesting that individual metabolic differences may impact 
the rate and progression of metabolism rather than the nature of the final metabolic 
product. Over time, within subjects, the size of the dose did not have any effect on the 
disposition of the enantiomers produced.50 In vitro experimentation with human liver 
enzymes has shown a preference for the formation of S-HHMA, but these results are 
contradicted by in vivo results. The reason for this contradiction remains unclear. In vivo, 
at CMAX there was instead more R-HHMA than S-HHMA.50 HHMA is an intermediary 
metabolite, and usually is subject to further metabolism in one of two possible ways, both 
of which involve phase II metabolic processes19,50. HHMA may be conjugated to produce 
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HHMA sulfate, or it may be instead subject to O-methylation by catechol-O-methyl 
transferase (COMT).19,50 Both of these metabolic processes exhibited a preference for S 
enantiomers in vitro.50 Such a finding could account for the higher CMAX found for R-
HHMA, as the S form may be preferentially consumed by metabolism. 
Factors Affecting Quality and Consistency of Kinetic Findings 
It is important to note that pharmacokinetic parameters differ widely between 
species, and even between individuals. The study performed by Kolbrich et al.	  e was the 
first to present data on a diverse cohort (paying attention to differences between sexes 
and races) on a longer timescale, and the authors examine pharmacokinetics following 
either a placebo (lactose), a low dose (1.0 mg/kg), or a high dose (1.6 mg/kg). MDMA 
was formulated as a salt, and the subjects remained seated in a quiet room for the 
duration of the experiment. T1/2, AUC∞, Vd/F, and CLF were calculated using 
noncompartmental models.57 Ultimately, 17 subjects completed the study. Data obtained 
with a “low dose” was compared to data obtained with a ”high dose” within the same 
subject.57 Because pharmacokinetic variables can change from person to person, the 
importance of having a large and diverse sample size cannot be understated. 
Table 4: Demographics of Study Participants57  
Mean Age ± SD 21.5 Yrs ± 2.5 
Age Range 18 – 27 Yrs 
Mean Weight ± SDf 76.7 kg ± 17.8 kg  
Male/Female 10/7 
The sample used by Kolbrich et al. contained a reasonable number of white individuals 
as well as black individuals, but only one Hispanic was included in the study. Additional 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
e For more information on the methods used, see Kolbrich et al., 2008 
f There was no significant difference in weight between males and females. 
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studies will be required in order to elucidate ethnic differences in the metabolism of 
MDMA, but the data presented here remains a good source for establishing baseline 
pharmacokinetic parameters of MDMA.  
Racial and Sexual Differences in Metabolism 
Mainly due to variations in the genes encoding the various hepatic enzymes which 
break down MDMA, there are differences in metabolism between individuals of differing 
genetic heritage. The gene encoding CYP2D6, a hepatic cytochrome involved in each of 
the relevant demethylenation reactions, may contain as many as 50 different alleles.57 
CYP2D6 activity is considered to be highly variable, and individuals may be classified as 
ultrarapid, extensive, intermediate, or poor metabolizers on the basis of their CYP2D6 
activity.601.4% of blacks were classified as poor metabolizers, while 4.5% of blacks were 
classified as ultrarapid metabolizers. 5-10% of whites may be poor metabolizers, and 
fewer than 5% of whites were ultrarapid metabolizers.57 COMT activity also shows high 
variability between groups of differing ethnicities.  These differences may offer one 
explanation as to the outliers found in many pharmacokinetic studies of MDMA 
metabolism.11,57  
Differences in the way MDMA is metabolized by males and females have also 
been described, and Kolbrich et al. expected to find “significant gender differences in 
MDMA pharmacokinetics…”; MDMA T1/2 was significantly longer in females in the 
“high dose” condition as compared to males. Kolbrich et al. found a greater MDMA 
CMAX for females, and the same is true for MDA.57 AUC∞ was also found to be greater in 
females than in males for both MDMA and MDA. It is important to note that such 
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differences were only significant in the “low dose” testing condition,57 although MDMA 
AUC∞ was trending towards significance in the “high dose” condition. This finding 
suggests that there are differences in the way MDMA is initially metabolized by the two 
genders, but that these differences may eventually become negligible. Concerning 
HMMA, CMAX was significantly lower in females in the “low dose” condition, and AUC∞ 
was found to be significantly lower in females in both the “low dose” and “high dose” 
conditions.57 This finding may be due to more rapid saturation/inhibition of O-
demethylenation reactions in females as compared to males, or perhaps alternatively to 
differences in COMT activity between sexes. One consequence of the gender-based gap 
in metabolic activity might be a significant difference in MDMA-related adverse 
reactions. 
V. Long-Term Effects and Neurotoxicity 
Investigational Difficulties 
Investigation of a compound like MDMA has many challenges. It is sometimes 
difficult to elucidate a clear cause of death in reported cases of MDMA-related fatalities, 
and there are many considerations that hamper efforts to draw definitive conclusions on 
the properties of MDMA. Perhaps the most salient is the nature of drug users; they use 
other drugs, which presents a confound. Describing this problem, McCann et al. suggest 
that “MDMA users, as a group, used more recreational drugs than control subjects and 
exposure to other drugs could have played a role in the cognitive or SERT deficits 
found.”97 The statistics also support the notion that many MDMA users are polydrug 
users. 98 Considering individuals seeking treatment for a drug problem in 2010, “ecstasy 
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was mentioned as the primary drug by 1% or less (almost 1000 clients in total) of 
reported treatment entrants in all European countries.”17(p54) In humans, experimental data 
can be difficult to interpret for additional reasons; it can be more difficult to control the 
amount of time in between drug exposure and experimentation and it is more difficult to 
normalize the degree of MDMA exposure between subjects. On some occasions, the 
subjects themselves are not able to definitively quantify how much MDMA they have 
taken, and people do not always tell the truth. In some cases, using a human subject is 
simply not possible or ethical. Making conclusive investigation more difficult, as 
described above, there can be differences between individuals with regard to MDMA 
metabolism and the body’s tolerance for the drug and its metabolites. In one case, an 
individual was found to have an MDMA CP of 7.720 µg/ml after having taken 42 pills. 
De Letter et al. suggest that blood concentrations above 1.000 µg/ml may be potentially 
lethal, and that levels at or below 0.6000 µg/ml may be capable of causing toxicity.68 The 
individual in this case complained of a hangover, and experienced hypertension and 
tachychardia.68 The reported plasma concentrations are more than seven times larger than 
what may have been a lethal concentration for many, yet the individual felt like he had a 
hangover. While this represents an extreme scenario, it is presented as an example of the 
tremendous variability in the effect of and tolerance to MDMA, and as a demonstration 
of the need for further research. De Letter et al. offer their finding of 76 MDMA-related 
fatalities, wherein CP,MDMA ranged from as low as 0.040 µg/ml to as high as 18.500 
µg/ml.68 It is therefore difficult to identify an LD50 which would be of any practical 
clinical utility. Of major concern, the range of doses taken recreationally overlap with 
	  39	  
those that produce toxicity or fatality.5 Further complicating matters, MDMA and its 
metabolites tend to redistribute themselves and even chemically react post-mortem, 
limiting the utility of autopsy.68 Because of the tremendous variability in MDMA 
tolerance, and the potential confounds present in many MDMA users as well as in cases 
of fatality, achieving a consensus on meaningful clinical variables can be difficult. The 
applicability of animal research is limited as well; findings based on animal research 
cannot be easily applied to human beings, as differing metabolisms, morphologies, and 
tolerances to MDMA limit the human relevance of any conclusions drawn. Studying the 
long-term effects of MDMA use is challenging in animals with different lifespans, but the 
study of human subjects presents its own challenges, beyond stricter ethical standards.        
Biological and Chemical Deficits in Humans  
Following MDMA administration in humans, a dose-dependent decrease has been 
found in 5-HT transporter sites as well as in 5-HT receptors, markers for 5-HT, and 5-
HIAA levels. This decrease persists even several weeks after ceasing to use the drug, and 
it is not clear how long a complete recovery may take, or if it is possible.4 This finding 
was first made in rats, but also holds true in humans.105 More recent studies have 
confirmed the finding in humans using an array of techniques including single photon 
emission computed tomography (SPECT), and positron emission tomography 
(PET).98,105–110 These changes are persistent and region specific, with the greatest losses 
found in regions of the HPC, striatum, and PFC.10 In order to assess functional damage, 
subjects may be exposed to stressful conditions which specifically seek to challenge the 
systems which may have been damaged. Such a test is especially sensitive to even small 
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deficits. In a study by McCann et al., MDMA users who had been abstinent for at least 
three weeks as well as MDMA-naïve controls were subjected to challenge by the mixed 
5-HT agonist meta-chlorophenylpiperazine (m-CPP), and the plasma levels of prolactin 
and cortisol were measured subsequently.  The MDMA using group was found to have 
significantly lower levels of both hormones.111 Concerning the previously described 
MDMA-induced changes in baseline cortisol levels,78,79 more long term neuroendocrine 
changes seem to exist. In regular MDMA users who had abstained for 3 weeks prior to 
testing, Gerra et al. found that baseline levels of cortisol as well as levels of ACTH were 
significantly higher than in controls.112 The authors exposed the subjects to stressful 
conditions, and consequently found significantly decreased levels of ACTH and cortisol 
in the abstinent MDMA users, as compared to controls, potentially indicating a blunted 
response to stress. 112 Taken together, these findings support the conclusion that there is a 
persistently diminished ability to deal with stress, which results from MDMA use. This 
finding differs from that seen in the acute response to MDMA administration described 
previously, where users had an elevated baseline cortisol level, but the magnitude of the 
change in response to stress was the same as in controls.77 Gerra et al. suggest that 
regular MDMA usage, by altering brain 5-HT (and possibly DA) neurons, may cause 
neuroendocrine dysfunction. 
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Biological and Chemical Deficits in Animals 
The previously described deficits in response to 5-HT challenge observed in 
humans may not be a finding exclusive to humans; as research has found deficits in 
reaction time and progressive ratio task in MDMA-exposed rhesus monkeys following 
challenge with m-CPP.  Morton et al., also report a diminished number of axonal 
projections from the dorsal raphe nucleus10, an observation made in rodents. Mueller et 
al. report that, in rodents, the amount of 5-HT depletion generated was found to correlate 
positively with the CMAX of MDMA and MDA.103 MDMA AUC, and not MDA AUC, 
was found to correlate with brain 5-HT deficits. Like MDMA, MDA is a known brain 5-
HT neurotoxin.113 It is not currently possible to pinpoint which pharmacokinetic 
parameter is most proximately related to neurotoxicity. Of great significance are the 
lasting changes in the density of the SERT. It is often difficult to assess particular long-
term deficits, as well as the extent of recovery, in human subjects. As discussed, this 
necessitates increased reliance on animal research, although the applicability of the 
findings to humans remains uncertain. Investigating the long-term effect of MDMA on 5-
HT1B  receptors in rats, Aguirre et al. have found opposite changes in receptor density in 
different regions of the brain. They found an increased density in the cortex, but a 
reduced density in the dorsal raphe nucleus.114 If the downregulation observed in the 
cortex was a response to elevated levels of 5-HT, then the upregulation observed in the 
dorsal raphe may be due to decreased or levels of 5-HT.114 Given that the 5-HT1 family 
of receptors often functions as an autoreceptor56(chap13), it is not surprising to find that this 
receptor is upregulated; the effect of this upregulation is to make the neuron more 
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sensitive to the 5-HT it is releasing, so that release can be more tightly controlled. The 
upregulation may be a response to long-term deficits. Further work by the same group 
has also noted an increase of 5-HT1A receptors in the rat hypothalamus, a region critical 
for regulation of body temperature.115 By contrast, the changes noted in the dorsal raphe 
nucleus were not always replicated in subsequent studies. Also looking in rats, McGregor 
et al. failed to find any difference in 5-HT1A receptor density in the dorsal raphe. Using 
SPECT and the radioactive 5-HT2A ligand [123I]R91150, Reneman et al. quantified 
cortical receptor density in rats who were recently exposed to MDMA, as well as in 
abstinent rats. Cortical 5-HT2A receptor density was lower in the rats who had recently 
used MDMA, but was actually higher in the abstinent group.116 This difference may be 
due to a compensatory upregulation in 5-HT2A expression consequent to diminished 
levels of 5-HT. In the group recently exposed to MDMA, the large amount of synaptic 5-
HT available for binding may have acutely caused downregulation of the receptor.52,116 In 
rats, MDMA has also been found to cause long-term decreases in tryptophan hydroxylase 
activity in several regions, notably the hippocampus (HPC), hypothalamus, and 
cortex.52,117,118 Such effects of MDMA use in animals are not limited to rats. Using the 
radioactive ligand[11C]McN5652 (which has an affinity for SERT transporters) in 
conjunction with PET scanning, deficits in markers for 5-HT have been observed in 
baboons at least 40 days after exposure to MDMA.119 
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Deficits in SERT Density 
SERT density is easily quantifiable, and reports of decreases in SERT density 
consequent to MDMA exposure have been described in many species, including humans, 
baboons, and rats.   
Figure 5: Autoradiograms Showing SERT Density120g 
a1-a4: Vehicle. b1-b4: low dose. c1-c4: high dose. Images span bregma +1.2 (left) to bregma -8.00 (right).  
Though the SERT density reductions described in Figure 5 were observed in rats, similar 
findings which have been previously described have also been made in non-humane 
primates, including baboons.119 In a study using ‘matched controls’ with respect to other 
recreationally abused drugs in order to account for to polydrug use (as mentioned above), 
McCann et al. were able to quantify SERT density using two different radiotracers in 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
g Adapted from McGregor et al., 2003. Used with permission. 
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conjunction with PET. In this particular study, the subjects (on average) had last taken 
MDMA 4.74 months prior, and the most commonly taken dosage averaged across 
subjects was 1.79 pills per exposure. The average number of lifetime exposures was 
96.96 per subject.98 
Figure 6h: PET Scans Displaying SERT Density in a Human Subject98 
 
SERT density is indicated by brightness. It is apparent from either radiotracer used that 
MDMA causes a reduction in the density of SERT expression. McCann et al. expanded 
on these findings several years later, further quantifying reductions in SERT density in 
particular regions of interest within the brain. This subsequent investigation used PET in 
conjunction with the radioactive SERT ligand [11C] DASB. In this study, the authors 
intentionally chose subjects who had a history of taking at least 2 doses of MDMA less 
than 12 hours apart.97 Subjects were abstinent from all drugs for two weeks prior to their 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
h Adapted from McCann et al., 2005. Used with permission 
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assessment. Ligand/SERT binding was assessed using distribution volume ratios (DVRs), 
a linear function of receptor availability.121  
Figure 7i: DASB Binding by Brain Region97  
 
Figure displaying DASB DVR + SD. # indicates p ≤ 0.05; * indicates p ≤ 0.01; ** indicates p ≤ 0.001; *** 
indicates p ≤ 0.0001. The regions investigated include MB midbrain, Amyg amygdala, HPC hippocampus, 
TH thalamus, CD caudate, Put putamen, DPFC dorsolateral prefrontal cortex, OC occipital cortex, OFC 
orbitofrontal cortex, PC parietal cortex, TC temporal cortex, ACC anterior cingulate cortex, PCC posterior 
cingulate cortex, Dpons dorsal pons, and Vpons ventral pons. 
 
Loss of SERT density is apparent in every cortical region assessed, as well as in the 
HPC97 and the amygdala, as would be expected given the previously described deficits in 
memory and higher cognition. Based on clinical observations, “the amygdala and the 
prefrontal cortex… are not only involved in processing emotions, but also participate in 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i Adapted from McCann et al., 2008. Used with permission. 
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the complex neural processing responsible for rational thinking.”55(p753) McCann et al. 
found that the correlation between SERT density and memory was actually stronger in 
controls than in MDMA users, and suggest that a compensatory response involving 
neuroplasticity may be working within the experimental group.97  
Functional Consequences in Humans 
Even after years of abstinence from MDMA, numerous deficits remain.8 These 
deficits include memory problems and cognitive deficits, psychiatric disorders, altered 
sleep architecture105, altered appetite, and reduced sexual interest.8 Retrospective memory 
deficits were the first memory problems to be identified122, with related deficits including 
diminished ability to perform immediate and delayed recall tasks being discovered 
subsequently.123–125 Deficits in prospective memory have also been reported126–128, and 
these appear to be dose-dependent, such that heavy MDMA users experienced a greater 
deficit than regular or infrequent users129. Deficits in cognition are most obvious in the 
execution of complex tasks; performance on simpler tasks (including reaction time and 
basic attention) is not impaired.130 McCann et al. first reported these deficits in 1999, but 
their existence and nature has been confirmed by subsequent research using a variety of 
cognitive measures.131–133 Examples of the type of complex task impacted by prior 
MDMA usage include complex decision tasks, such as the Brixton Spatial Anticipation 
task.4,133 Those who use MDMA risk developing cognitive deficits in logical reasoning, 
executive processing, and emotional intelligence.4 One study by Halpern et al. was able 
to isolate a group of individuals with minimal exposure to other neurotoxic substances, 
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and one interpretationj of their data33 indicates the presence of the previously mentioned 
deficits, implicating MDMA exposure as the salient factor.30k  
Pathological changes in sleep architecture are another feature of MDMA use. 5-
HT is just one neurotransmitter which influences sleep and circadian rhythms55(p141),134, 
and since MDMA is a known 5-HT neurotoxin105 with long-term effects, it is likely that 
patterns of sleep and circadian rhythms may become disrupted due to MDMA. 
Furthermore, it is possible that sleep disruptions may lead to other cognitive deficits if 
normal sleeping patterns are disrupted for extended periods. Such progression may 
explain deficits observed in abstinent MDMA users.105 In clinical studies with humans, 
abstinent MDMA users were found to have significantly less total sleep (both REM and 
NREM)l with significantly less stage 2 sleep.135 In a follow-up study of 25 age and 
gender matched abstinent MDMA users, the previously described reduction in stage 2 
sleep failed to reach significance.136 While it is not clear why this result failed to reach 
significance in a subsequent study, possible explanations include differences in the 
amount of MDMA administered and the duration of abstinence from MDMA. 
Additionally, the authors found significant increases in both stage 3 and stage 4 sleep in 
the experimental group. They also reported increased sleep disordered breathing (apneas 
and hypopneas)105,136 In another paradigm of the same study, the subjects were also 
exposed to the mixed 5-HT m-CPP. The result was an increase in time spent in stage 4 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
j See page 6 for more details on the controversy surrounding this study’s findings. 
k This previously described study was met with several responses after reportedly observing an 
absence of MDMA-induced neurotoxicity. We have applied A.C. Parrott’s interpretation of the 
data gathered by Halpern et al. 
l REM, or Random Eye Motion, is a phase of the sleep cycle. NREM, or Non Random Eye 
Motion, refers to all phases of sleep where REM is not occurring.  
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sleep within the experimental group, but a decrease in time spent in stage 4 sleep within 
the control group. This paradoxical finding supports the idea that MDMA leads to major 
changes in the control of sleeping patterns, and that the function of 5-HT neurons in 
MDMA users differs from that in controls.105,136 
Functional Consequences in Animals 
Lifetime deficits in social behavior, associated with decreased levels of 5-HIAA, 
have been observed in rats. 8 In a study by Fone et al., the authors gave male rats a large 
(7.5 mg/kg) dose of MDMA twice daily for 3 days. When considering the rats’ behavior 
12-29 days following the final injection, the authors found a 41% decrease in social 
behaviors.137 A similar finding was also reported by McGregor et al. In this particular 
study, male rats were divided into 3 groups of 12 rats each: a high dose group, a low dose 
group, and a vehicle (control) group. Considering the half-life of MDMA in rats, drug 
administration methodologies were meant to be as similar as possible to human 
consumption patterns. The high dose group received an injection every hour for 4 hours 
over two consecutive days; each injection was 5 mg/kg. The low dose group received one 
5 mg/kg dose in total.120 Social behavior was assessed ten weeks later. 
Table 5m: Social Interactions Following MDMA Administration in Rats120  
Group Time Spent Interacting 
[Secs] (SEM) 
Number of Interactions 
(SEM) 
Vehicle 120.63 (8.05) 56.25 (3.27) 
Low dose 72.98 (4.03)§ 47.00 (3.42) 
High dose 56.31 (4.85)§★ 42.67 (2.28)§ 
★: Significant with respect to low dose group. § Significant with respect to vehicle group. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
m Adapted from McGregor et al., 2003. Used with permission. 
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McGregor et al. also found significantly reduced levels of 5-HT and 5-HIAA in the PFC, 
striatum, HPC, and amygdala.120 These results clearly demonstrate the lasting effects of 
MDMA use on social behaviors and on the 5-HT system, even weeks after the cessation 
of MDMA use. In addition to social deficits, one study by Balogh et al. looked at the 
effects of MDMA on a number of parameters, including sleep and circadian rhythms, in 
rats. As might be expected upon administration of an amphetamine analog, patterns of 
sleep and motor activity were disrupted for at least 6 hours following a single systemic 
dose of MDMA to drug-naïve rats. The effect was much more pronounced in rats that had 
been pretreated with MDMA three weeks prior; circadian sleep and motor activity 
rhythms were disrupted for about 5 days.105,138 Alterations in motor activity, wakefulness, 
and slow-wave (deep) sleep remained apparent a full month after MDMA administration, 
the last data collection point.105,138 Reaching the same finding as previous research96, 
there was also a reduction in paroxetine binding to SERTs located on neurons in the 
cortex. 105,138 
 
VI. Hypotheses on the Etiology of MDMA-Mediated Neurotoxicity 
The Role of MDMA Metabolites 
The mechanism behind neurotoxicity remains unclear, as neither MDMA nor its 
metabolites MDA, HHMA, and HMMA were found to produce serotonin toxicity when 
injected into the rat brain.57 Mueller et al. administered 20 mg/kg of MDMA to rats 
orally, measuring brain concentrations of MDMA and metabolites at various time points. 
Only MDMA and MDA were found in the brain at every time point considered. 103 
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Furthermore, the concentrations of MDMA and MDA in the brain were found to 
significantly correlate with their respective plasma concentrations; this was not true for 
other MDMA metabolites such as HHMA.103 Neither HHMA nor HMMA were 
detectable in significant quantities in the brain, leading Mueller et al. to hypothesize that 
neither of these substances readily cross the blood-brain barrier, and that there is a 
negligible amount of brain metabolism producing these substances.103Further research 
has been done on the compounds HHMA and HHA, and in both cases the authors 
concluded that neither compound could be wholly responsible for the neurotoxicity 
produced by MDMA.103 Regardless, the finding that a direct injection of MDMA into the 
brain fails to produce toxicity has led to questions about the roles of MDMA metabolites 
created elsewhere in the body.103 As mentioned previously, hepatic metabolism aims to 
conjugate MDMA or its metabolites to hydrophilic moieties, so that they can be excreted 
in the urine. Mueller et al. note previous work suggesting that some products of hepatic 
metabolism may be neurotoxic; “glutathione and N-acetylcysteine conjugates of catechol 
metabolites of MDMA and MDA have been identified and implicated in MDMA 
neurotoxicity”.103 The catechol metabolites of MDMA may (HHMA, HHA) become 
oxidized, forming their respective quinones. These quinones are able to form adducts 
with thiol-containing compounds, including glutathione. One such metabolite, 5-(N-
acetylcystein-S-yl)-3,4-dihydroxymethamphetamine (5-NAC-HHMA) has been 
suggested as a possible cause of toxicity.103,139,140  
Mueller et al. injected 5-NAC-HHMA at two different doses directly into the 
striatum of rats. Modest, non-significant reductions in indole levels were found, but were 
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not dose-dependent and could not be blocked by pretreatment with fluoxetine, which is 
known to prevent 5-HT toxicity.103 Injection of an MDMA metabolite such as 5-NAC-
HHMA into a particular area of the brain may not adequately model the conditions that 
produce toxicity. This is offered on the basis that the complex interaction of 
neurotransmitters (5-HT, DA, etc.) may be necessary, and a locally administered 
injection may not be an accurate model of such an interaction.103 Furthermore, 
compounds causing MDMA-like toxicity have not been demonstrated to form quinones 
as a result of metabolism. Quinone formation is a necessary component of the toxic 
metabolite hypothesis.141 The significance of 5-NAC-HHMA and other metabolites in the 
production of MDMA-induced neurotoxicity is a topic of continued investigation. 
The Role of Reactive Oxygen Species 
Although MDMA is a 5-HT neurotoxin105, its effects on other neurotransmitters 
may be important when considering the mechanism by which toxicity is produced, 
especially since DA release has been found to correlate with the degree of SERTs lost. 
1,142,143 As noted by others, MDMA is “messy”.8 Sprague et al. note that the production of 
reactive oxygen species (ROS) is necessary to produce 5-HT toxicity in rats. ROS 
production may occur as a result of deamination or autooxidation of DA;141 DA is a 
relatively reactive compound. Since DA release has been found to correlate with the 
degree of SERTs lost1,142,143, this hypothesis is especially attractive, although it may be 
just one part of a larger mechanism, or completely coincidental. Investigators continue to 
debate the veracity of the claim that MDMA-induced toxicity144 is a result of ROS, and 
some have likened the situation to that of the chicken and the egg.145 Jones et al. have 
	  52	  
demonstrated that the observed increase in ROS production takes place in cells 
possessing the SERT.146 DA is not the only potential cause of ROS generation. 
Jones et al. have found that two specific glutathione adducts (specifically the 
thioethers 5-(Glutathion-S-yl)-α-methyldopamine and 2,5-bis(glutathion-S-yl)-α-
methyldopamine, which are glutathione adducts of HHMA and HHA, respectively) are 
potent generators of ROS. Thioether-metabolites may oxidize the cell membrane via a 
ROS-mediated mechanism. Jones et al. also found that that these two compounds cause 
the uptake of DA into cells possessing SERT.141,146 The DA may then become reactive as 
previously discussed, creating multiple sources of ROS. In this model, the glutathione 
adducts are responsible for the uptake of DA into cells possessing SERT. The DA then 
causes an increase in ROS, which may damage the neuron. The increase in ROS is both 
time and concentration dependent.146 Capela et al. corroborate these findings, suggesting 
that the thioether metabolites of HHMA and HHA may be far more neurotoxic than their 
parent compounds.147 Additionally, MDMA and MDA themselves have been shown to 
cause a somewhat less pronounced uptake of DA into cells expressing SERT.146  
In addition to the uptake of DA into cells expressing SERTs, the thioether 
metabolites of HHMA and HHA, products of conjugation with glutathione or N-
acetylcysteine, produced a concentration-dependent delayed neuronal death, with 
accompanying activation of caspase 3.147,148 This finding strengthens the relevance of the 
correlation between DA release and 5-HT neurotoxicity, and offers a possible 
explanation. As previously mentioned, Mueller et al. found that direct injection of 5-N-
acetylcysteine-HHMA did not produce the expected amount of 5-HT toxicity when 
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injected directly into the striatum of a rat.103 This result weakens the hypothesis that this 
metabolite is responsible for producing toxicity, although it is possible that the MDMA-
induced toxicity ordinarily observed in humans is a result of the synergistic action of a 
number of metabolites as well as the parent compound (MDMA) itself. Such synergistic 
effects may produce toxicity by cooperatively increasing the oxidative load beyond the 
cell’s ability to cope, or through other mechanisms. DA is extremely reactive and may 
produce ROS, and as discussed, activation of 5-HT2A may lead to increased DA 
synthesis.149,150 Capela et al. succinctly described the hypothesis: “5-HT2A-receptor 
stimulation produces intracellular oxidative stress that leads to neuronal apoptosis 
accompanied by caspase 3 activation.”148 Adding to the oxidative burden, it is possible 
that the extreme degree of cellular activity caused by the activity of MDMA contributes 
to neurotoxicity, and some have proposed that this effect mediates the increased 
production of ROS.8  
Dopamine, Temperature, and MDMA 
The extent of the deficits in SERT caused by MDMA seems to positively 
correlate with the amount of DA released1,142,143. One explanation for this phenomenon 
suggests that activation of the 5-HT2A receptor leads to increased production of DA. The 
previously described action of MDMA at 5-HT2A receptors10 may activate the receptors; 
activation of 5-HT2A, either by the endogenous ligand 5-HT or by MDMA may lead to 
increased DA synthesis149,150, partially explaining the observed correlation.n  
Furthermore, in rats, extracellular DA levels as well as the extent of serotonergic toxicity 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
n MDMA produces 5-HT toxicity, and causes release of 5-HT. Release of 5-HT causes increased 
dopamine synthesis through action at this receptor.  
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caused by MDMA administration were found to be reduced by pre-treatment with 5-
HT2A antagonists.1,151,152. Malberg et al. administered α-methyl-p-tyrosine (AMPT), an 
inhibitor of tyrosine hydroxylase, to reduce DA levels.151 Consequently, they observed a 
reduction in the neurotoxicity produced by MDMA.  The other significant finding was 
that pretreatment with AMPT, followed by administration of MDMA, produced a marked 
and long-lasting hypothermia in the rats.151 As discussed, research by Brown and 
Kiyatkin as well as others has demonstrated the neuroprotective effects of lower 
temperatures, such that higher temperatures exacerbate MDMA-induced toxicity.8,71 
Since 5-HT2A antagonists were found to cause hypothermia, it is possible that 
hypothermia, and not reduced DA levels, was responsible for the observed 
neuroprotection. In a study by Yuan et al., both vesicular and cytosolic DA were depleted 
using AMPT and resperpine (which inhibits VMAT).153 Upon administration of MDMA, 
the rats were prevented from experiencing hypothermia by increasing the temperature of 
the environment. The neuroprotective effects which were previously thought to derive 
from reduced levels of DA disappeared,153 indicating that the neuroprotection observed 
by Malberg et al. and others was actually due to hypothermia, not lower DA levels. One 
important conclusion that can be drawn from these findings implicates DA in the 
generation of hyperthermia, a hypothesis which has been suggested by multiple 
studies.154,155 Hyperthermia might result from activation of D1 receptors by DA.52,156 
Effects Relating to Temperature  
The role of temperature in MDMA-induced neurotoxicity has been well 
documented. Working with rats, Brown and Kiyatkin administered 9 mg/kg of MDMA at 
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a variety of temperatures, in settings meant to mimic the ways in which humans self-
administer MDMA.71 Brown et al. were especially interested in the effects on the nucleus 
accumbens (NACC) and the HPC. At 23 °C, MDMA produced a moderate hyperthermia; 
the temperature gains in the NACC and HPC were greater than those found in muscle, 
suggesting that the brain’s metabolic activity may be to blame for the increase in 
temperature.71 The temperature increase in these two brain regions was also more rapid 
than in muscle. When social interaction with a female was added to the experimental 
condition, the hyperthermia observed in the NACC and HPC was significantly 
potentiated.71 When MDMA was administered at 29 °C, hyperthermia pushed the 
temperature in the brain to its biological limit (over 41 °C), resulting in fatality.71 Of 
further concern is the notion that hyperthermia potentiates neurotoxicity.157 This is yet 
another reason why small variations in dose or environment can lead to large changes in 
the severity of the outcome. As noted by A.C. Parrott, elevated temperatures (including 
those caused by an elevated ambient temperature) can worsen serotonergic toxicity, while 
lower temperatures afford some degree of neuroprotection.8  
Differences in Toxicity and Cause of Death Between Genders o 
Data from multiple sources, both clinical and pre-clinical, suggest a sexually 
dimorphic pattern of pathology produced by MDMA. Adult females appear more 
sensitive to the acute and sub-acute physiological and psychological effects of MDMA, 
as well as to the long-term changes in 5-HT systems.102 Considering the pharmacological 
differences in metabolism previously discussed, it is not surprising that women are also 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
o For a comprehensive review of the sexual dimorphisms associated with MDMA, see Allott and 
Redman, 2007. 
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more likely to experience adverse responses to MDMA, when given the same bolus dose 
as a male. Individuals with lower body weights, as are found in many women, may be 
more susceptible to hyponatraemia.4 Analyzing 1407 cases of MDMA-related 
hyponatraemia, Rosenson et al. found women were significantly more represented than 
men.95 Considering individuals who attended a particular Dutch “rave” in 2010, Van 
Dijken et al. analyzed the plasma sodium concentration of 63 subjects who had taken 
MDMA. The authors found mild hyponatraemia in 25% of females, but only 3% of 
males, even though there was no significant difference in the rate of pill consumption 
between individuals.4,158 
 
VII. Conclusions 
The chemistry, disposition and metabolism, and biological effects of MDMA 
have been detailed. Potential adverse effects, including serotonin neurotoxicity, have also 
been discussed. Exploring the history of MDMA, we have seen the ways in which the 
pattern of MDMA use is changing, such that it is now more commonly taken in private 
homes than in nightclubs or concert venues. At the same time, the frequency of MDMA-
related hospitalizations has risen. There appear to be two vocal groups with strong 
opinions regarding MDMA; one group advocates its use as a novel psychotherapeutic 
adjunct, while the other emphases its potential fatal properties. The more likely risks 
associated with MDMA include the described long-term serotonergic deficits and 
pathological consequences, but the etiology of these effects is not well understood, and 
not all of the effects associated with MDMA use have been well described in humans. In 
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other words, the public discourse on MDMA is confusing and frequently misrepresented. 
As noted by A.C. Parrott, “Perhaps the most important [issue] is the very misleading 
message for the general public (at-risk youngsters in particular) that MDMA is safe for 
human consumption, and that MDMA can help solve your personal problems”.4 The 
confusing state of public discourse in many ways reflects the confusing state of current 
scientific opinion on MDMA. Until more details relating to MDMA’s mechanism of 
action, particularly the mechanisms underlying MDMA-induced 5-HT injury and 
associated functional consequences, those who wish to use MDMA should proceed with 
caution, with due considerations of risks and benefits.  
The range of responses to a given dose of MDMA can be highly variable between 
individuals, and because its metabolism is non-linear, small changes in dose can lead to 
large changes in plasma concentrations. This effect may be expected to increase the 
chance for errors in dosing, and is another reason recreational use of MDMA should be 
done cautiously. Further contributing to the unpredictable effects of “ecstasy” use, it is 
impossible to know what kinds of impurities are contained in a dose of the drug bought 
illegally. MDMA may not even be present.  The need for continued research on the 
effects and mechanisms associated with MDMA is more pressing than ever. 
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APPENDIX 
Appendix 1a: Mean CMAX, TMAX, and AUC∞ for MDMA & HMMA57,p 
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
p Adapted from Kolbrich et al., 2008. Used with permission. 
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Appendix 1b: Mean CMAX, TMAX, and AUC∞ for MDMA & HMMA (continued)57,q 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
q Adapted from Kolbrich et al., 2008. Used with permission. 
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